Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

With MAB rolling out we have the potential for a similar ramp up throughout 2104, thus adding about $10-20 million in revenue for this FY. This amounts to $50-70 million for FY2014 for just the two SC products MAB and Herceptin. This could push us over the top into profitability for year's end. Moreover, FY2015 might look like a total of $150 million just from the two sources - roughly a buck a share.
All numbers are very rough guess-timates and may be further clouded by their wierd accounting proclivities but a good solid trend is in the making, IMHO.
Good luck!
-Fritz